Skip to main content
Genexine, Inc. logo

Genexine, Inc. — Investor Relations & Filings

Ticker · 095700 ISIN · KR7095700001 KO Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2023-05-03 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 095700

About Genexine, Inc.

http://www.genexine.com/

Genexine, Inc. is a clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation biologics. The company utilizes its proprietary hyFc® platform technology to create long-acting protein therapeutics. Its pipeline is led by GX-I7, a long-acting interleukin-7 designed to amplify T-cell counts for immuno-oncology applications. Other key assets in late-stage clinical trials include GX-E4, a long-acting treatment for anemia, and GX-H9 for growth hormone deficiency. Genexine's research and development efforts primarily target oncology and rare diseases.

Recent filings

Filing Released Lang Actions
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Genexine regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. It details the number of shares issued, the conversion price, and the impact on total shares outstanding. This type of filing relates to changes in capital structure due to the conversion of debt into equity, which falls under the 'Share Issue/Capital Change' category.
2023-05-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and details the outcomes of the shareholder meeting held on 2023-03-30, including the approval of financial statements, director appointments, and remuneration limits. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), which covers official results from shareholder votes at general meetings.
2023-03-30 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Genexine. It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the current and previous fiscal years. According to the 'Menu vs Meal' rule, this is an announcement of the audit report submission rather than the full, multi-page audit report document itself. In the context of Korean regulatory filings (DART), this specific format is a standard disclosure announcement regarding the filing of an audit report. FY 2022
2023-03-20 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2022 (2022.01.01-2022.12.31) for Genexine, Inc. It contains comprehensive financial statements, management discussion and analysis, auditor's opinion, and detailed business operations. This structure corresponds to the standard annual filing required by the Financial Supervisory Service (FSS) in South Korea, which is equivalent to a 10-K filing. FY 2022
2023-03-20 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Genexine, Inc. It contains the meeting agenda, details on electronic voting, and financial statements (balance sheet, income statement, etc.) as part of the meeting materials. According to the filing definitions, documents detailing materials shared for an AGM are classified as AGM-R.
2023-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains details about the meeting, the agenda (such as approval of financial statements, election of directors, etc.), and instructions for electronic voting. While it contains financial data, it is a proxy solicitation document rather than an Annual Report or Earnings Release. Therefore, it falls under the 'Proxy Solicitation & Information Statement' category.
2023-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.